Kolexia
Rigaudeau Sophie Hématologie
Rigaudeau Sophie
Hématologie
Centre hospitalier de Versailles
Le Chesnay, France
72 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Leucémies Tumeurs à plasmocytes Leucémie myéloïde Leucémie aigüe myéloïde Lymphomes COVID-19 Leucémie myéloïde chronique BCR-ABL positive Leucémie lymphoïde

Collaborateurs

Voir plus
Rousselot Philippe
Rousselot Philippe
Hôpital Saint-Louis, Paris, France
Merabet Fatiha
Merabet Fatiha
Centre hospitalier de Versailles, Le Chesnay, France
Besson Caroline
Besson Caroline
Centre hospitalier de Versailles, Le Chesnay, France
Taksin-Bressot Anne-Laure
Taksin-Bressot Anne-Laure
Centre hospitalier de Versailles, Le Chesnay, France

Industries

Voir plus
Sanofi
12 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2023
Janssen
3 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RHUMM: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma RHU(M)M Random or H24 Urine in (Multiple) Myeloma
Essai Clinique (Intergroupe Francophone du Myélome)   15 mars 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
65th ASH Annual Meeting Abstracts   02 novembre 2023
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Essai Clinique (Millennium Pharmaceuticals)   20 juillet 2023
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
American journal of hematology   01 janvier 2023
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
Annual Meeting Abstracts 2022   15 novembre 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners   06 septembre 2022
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
Leukemia & lymphoma   18 juin 2022